Dataset opportunity
Innovaderm — 医疗影像数据集机会
Innovaderm 持有的中等规模医疗影像数据集，可用于诊断人工智能和计算机视觉。
Score
64.9
Score (0–100) blends weighted dimensions — dataset rarity, training value, buyer demand, evidence strength and right-to-license. 70+ is deal-ready. See the scored dimensions below for the breakdown.Confidence
49%
Action
数据共享协议
The recommended deal structure for this dataset: Acquire (full buyout), License (paid usage rights), Data Sharing Agreement (controlled access, no transfer of ownership), Partnership (co-development) or Annotation Program (labeling). Chosen from data ownership, licensing complexity and accessibility.Market size (indicative estimate)
全球诊断人工智能市场规模在2023年估值为12亿美元，预计到2030年将以24.60%的复合年增长率增长。
Lineage
How this lead was derived
The signal-first chain, end to end: recent external signals → qualified niche → resolved data-holder → site verification → scored opportunity. Every lead is explainable.
Concrete evidence this company actively cares about data — why it's ripe for the deal room.
Profile
Dataset profile
Type
医疗影像数据集
Modality
图像
Sector
医疗保健
Volume
中等
Freshness
定期
Rarity
中等
Accessibility
受限
Legal
混合所有权 — GDPR敏感（PII审查）
Buyer persona
医疗人工智能与诊断影像公司
Innovaderm 拥有一个庞大的医疗影像数据集，包含来自皮肤科临床试验的高质量图像，系统地组织了`data_catalog`并链接到相应的`medical_records`。这种结构化的集合非常适合训练、验证和测试诊断人工智能算法，提供真实世界的数据来开发用于皮肤科自动化分析和病理检测的工具。
该数据的商业价值体现在全球医疗诊断人工智能市场上，该市场在2023年的估值为12亿美元，预计将以24.6%的复合年增长率扩张。[1] 虽然访问受到严格去标识化的限制以保护高度敏感的健康数据，并且需要与试验申办方协调共享所有权，但该数据集的稀有性和临床特异性使其成为在快速增长的市场中创造竞争优势的宝贵资产。⚠ 尽职调查（有价值的数据，可协商访问）：高度敏感的健康数据（PHI），需要严格的去标识化和监管合规性（PIPEDA/GDPR）。；特定试验结果的所有权通常与制药申办方共享或由其持有；临床数据的二次使用需要特定的患者同意或伦理委员会批准。· 公司：独立。
Scoring
Scored dimensions
Explainable, evidence-based dimensions (0–100). The radar shows the investment axes.
证据证实Innovaderm拥有一个庞大的、经过临床验证的医疗影像数据集，该数据集来自2000年以来超过500项皮肤科临床试验。该集合是医疗人工智能公司开发诊断人工智能工具的主要资产，提供了稀有的结构化、纵向数据来源，用于训练和验证算法。在全球诊断人工智能市场预计每年增长超过24%的情况下，该数据集为构建准确的、专业化的皮肤科模型提供了关键的竞争优势。
See dimension details ↓- Dataset Specificity78
主导的'medical_records'，医疗保健行业，2种特定类型
How sharply the data targets a specific, hard-to-substitute domain or task. Niche, well-defined data scores higher than generic. - Dataset Rarity46
专有领域数据（开放会降低稀有度）
How scarce and proprietary the data is. Unique domain data scores high; openly available data lowers it. - Dataset Volume52
3个证据命中
Apparent scale of the data, inferred from the number of evidence hits and any explicit volume mentions. - Dataset Freshness62
API/开放（当前）
How current the data stays — real-time/streaming scores highest, periodic dumps lower. - Training Value74
适用于诊断人工智能
How useful the data is for the target AI use-case — its fit for model training or fine-tuning. - Buyer Demand90
买家需求异常高，这得益于快速增长的**12亿美元**市场和人工智能驱动的诊断解决方案强劲的**24.6%复合年增长率**。[1]
How strongly AI builders and companies are likely to want this data, based on market signals. - Legal Accessibility14
开放/API访问
How legally easy the data is to obtain and use — open/API access scores high; PII or regulated data scores low. - Acquisition Feasibility48
中等难度，独立
How realistic it is to actually obtain the data, given access difficulty and the holder's corporate structure. - Evidence Strength62
3种证据类型，3次命中
How solid the proof is that the company holds this data — diversity of evidence types and number of hits. - Right to License28
所有权=混合，许可=gdpr_敏感
Whether the company can legally license the data out — based on ownership and licensing complexity. - Corporate Independence90
独立
Whether the holder can decide alone — an independent company scores higher than a subsidiary of a large group. - Data Orientation73
3个数据需求信号（3种类型）
How actively the company invests in data, measured by its data-appetite signals (hires, products, APIs…). - Dormant Data Surplus92
盈余=高 — 专有数据超出已货币化的部分
Volume and value of proprietary data this company holds BEYOND what it already monetises — the dormant surplus we can unlock. A company can sell some insights AND still sit on a far larger dormant asset. - ICP Audit75
✓ 良好目标 — 该公司是一家专业的合同研究组织（CRO），其核心服务业务的副产品是生成有价值的临床试验数据，使其成为一个潜在的良好目标。问题：主要问题是数据所有权：作为一家CRO，他们生成的数据很可能归其客户（试验申办方）所有，而不是归他们自己所有，这严重限制了；核心CRO业务最近从Innovaderm更名为'Indero'，以反映其在风湿病学领域的扩张。[13, 15, 16]
- Deep Qualification90
⚠ 需要审查 — Innovaderm是一家临床研究单位（CRU），为制药申办方提供服务，并在此过程中生成皮肤科临床试验数据。然而，数据归试验申办方所有，并且该公司的隐私政策明确禁止出售个人信息，这使得它成为一个具有挑战性的收购目标。[数据归公司客户所有；许可受限]
Evidence
Dataset evidence & lineage
What the typed evidence proves the company holds — reframed for clarity and set against the market.
Medical records / imaging
该数据集源于500多项皮肤科临床试验的历史，为训练和验证诊断人工智能模型提供了丰富的纵向图像来源，具有很高的证据价值。
Image collection
图像在专用临床环境中，使用专业设备捕获，确保了高质量、标准化的集合，非常适合开发精确的医疗影像算法。
Data catalog / marketplace
持有方运营着一个专有的患者招募平台，展示了其为未来数据集扩展或定制项目提供多样化皮肤科数据来源的可扩展且持续的能力。
Marketplace
Dataset details
Detailed schema & sample available on access request.
Want this data?
Request access — we broker a secure deal room. Operator-reviewed, no automatic sharing.
This listing was generated automatically from public signals. It is not verified, and we are not affiliated with this company.
Coverage
Scanned sources
Deliverable
Premium dataset report
Innovaderm Medical Imaging — a Moderate medical imaging dataset (Image modality) in the healthcare domain. Primary AI use-case: Diagnostic AI. Market signal: Global AI in diagnostics market size was valued at $1.2 billion in 2023, projected to grow at a CAGR of 24.60% through 2030 (source: Grand View Research). [1]. Investment score 64.9/100 (confidence 0.49). Recommended action: Data Sharing Agreement.
From the marketplace
Explore live data opportunities
Baerenkaelte — 维护日志数据集机会
View opportunity →工业Gtm Gmbh — 检验报告数据集机会
View opportunity →医疗保健Ensoma — 医疗影像数据集机会
View opportunity →